Description

This fund primarily allocates its capital to common equities. A substantial portion, specifically at least 80% of its total assets, is dedicated to companies deeply involved in the biotechnology industry. This encompasses businesses engaged in the research, development, manufacturing, and distribution of biotechnological products, services, and processes, as well as those poised to benefit significantly from scientific and technological advancements in the field. Its investments span both domestic and international issuers. To select holdings, the fund employs a rigorous fundamental analysis, evaluating factors such as each company's financial strength, its competitive position within its industry, and broader market and economic conditions. It operates as a non-diversified fund.